Improvement of
Movement Disorders
with Mirtazapine: To
Preliminary Open
Trial
NOTE: Translated
using software of
translation of
Spanish to English
SUMMARY:
We
performed a non-controlled open trial in 22 patients who had movement
disorders. Patients received 30 mg of Mirtazapine per day. Twenty
patients (90.9%) had a favorable response and their scores on the severity
and functional scale improved after treatment. The time needed to control
abnormal movements was 30 days in almost 70% of the subjects. Further
randomized controlled trials could determine the effectiveness of
Mirtazapine for movement disorders.
Author:
Ecuadorian
magazine of neurology
